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Abstract. The exploration of new antimicrobial combinations is a pressing con-
cern for Clinical Microbiology due to the growing number of resistant strains 
emerging in healthcare settings and in the general community. Researchers are 
screening agents with alternative modes of action and interest is rising for the 
potential of antimicrobial peptides (AMPs). This work presents the first ever 
network reconstruction of AMP combinations reported in the literature fighting 
Pseudomonas aeruginosa infections. The network, containing 193 combina-
tions of AMPs with 39 AMPs and 154 traditional antibiotics, is expected to help 
in the design of new studies, notably by unveiling different mechanisms of ac-
tion and helping in the prediction of new combinations and synergisms. The 
challenges faced in the attempted text-mining approaches and other considera-
tions regarding the manual curation of the data are pointed out, reflecting about 
the future automation of this type of reconstruction as means to widen the scope 
of analysis. 
Keywords: Antimicrobial peptides, drug synergism, interaction network, Pseu-
domonas aeruginosa infections. 
1 Introduction 
Clinical Microbiology is currently facing major challenges regarding the discovery 
and/or design of new antimicrobial agents and the development of novel antimicrobial 
strategies. Drug and even multi-drug resistant (MDR) strains are emerging with in-
creasing frequency, and rendering ineffective many conventional antibiotic treat-
ments. Therefore, research is focused on finding alternatives to keep new resistance 
from developing and to prevent the resistance that already exists from spreading, ei-
ther by discovering biomolecules with antimicrobial potential and different mode of 
action, or by combining agents and potentiating their efficacy. Notably, there is a 
growing interest in the use of antimicrobial combinations as a strategy to increase the 
antimicrobial spectrum, prevent the emergence of resistance, reduce toxicity and side 
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effects and provide synergistic activity. In fact, synergy testing has been encouraged 
to guide clinical treatments for MDR strains, namely Pseudomonas aeruginosa asso-
ciated pulmonary exacerbation [1].  
Although combinations may be accomplished by using traditional antimicrobials, 
the most promising strategy at the moment is the use of novel antimicrobials with new 
mechanisms of actions, either combined with each other or with traditional com-
pounds. Notably, antimicrobial peptides (AMPs) are short-length peptides (between 
15 and 30 amino acids) that exert activity against a broad spectrum of microorgan-
isms, such as Gram-negative and Gram-positive bacteria (including drug-resistant 
strains), and are effective both in planktonic and biofilm scenarios [2]. These peptides 
have been recognized as promising candidates to replace classical antibiotics due to 
their multiple mechanisms of action and low specificity in terms of molecular targets, 
which reduces the chance of acquired resistance [3]. Besides, AMPs can influence 
processes which support antimicrobial action, like cytokine release, chemotaxis, anti-
gen presentation, angiogenesis and wound healing [4]. 
Recent advances in large-scale experimental technologies have resulted in an ac-
cumulation of data that reflect the interplay between biomolecules on a global scale. 
Bioinformatics approaches, such as network reconstruction, can help in profiling and 
interpreting the activity of AMPs and thus, in exploiting their potential as antimicro-
bial drugs. Networks can be used to map the interaction data outputted by combina-
tion studies, can be explored to unveil new interactions at the global scale, and also to 
classify new drugs by their mechanism of action [5]. In particular, the investigation of 
antimicrobial combinations has been supported by network models that have demon-
strated that the partial inhibition of few cell targets can be more efficient than the 
complete inhibition of a single target [6].  
Pharmacological networks can be constructed and integrated from heterogeneous 
and complementary sources of chemical, biomolecular and clinical information, but 
most of the information related to drug combinations is scattered over scientific litera-
ture. Manual curation is effort and time consuming, and virtually unfeasible if a  
systematic and up-to-date screening is desired. In this regard, some works have intro-
duced text mining approaches to mine drug information. Most of these works focus 
on drug-drug interactions (DDIs), which are related to adverse events of combinations 
of available drugs, usually targeting the same gene or pathway [7].  
The aim of this work was to reconstruct the first ever AMP interaction network. 
Currently, several databases collect AMP related data, namely sources, targets and 
minimum inhibitory concentrations [4]. However, it is difficult to find information 
about AMP interactions in these databases. Scientific literature is the primary source 
of data and thus, the use of text mining tools was investigated to alleviate manual 
curation. The application of AMP-based therapies to the treatment of infections 
caused by the bacterium P. aeruginosa, one of the most studied pathogenic microor-
ganisms, was chosen as proof-of-concept to the development of a more systematic 
reconstruction framework.  
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2 Materials and Methods 
PubMed was searched for papers on synergistic interactions including AMPs. Specifi-
cally, we required the presence of any variant of the term synergism, using synergis* 
(where the * is a wildcard), following the query “antimicrobial peptide Pseudomonas 
aeruginosa”. Then, we manually curated the interactions described in the papers 
yielded by the search, with at least on AMP as one of the combined antimicrobials. 
These interactions were represented in a network where nodes identify antimicrobial 
agents and edges encode the interactions among agents. Edge labels encode infor-
mation on experimental evidence, such as P. aeruginosa strain(s), mode of growth 
(planktonic, biofilm and in vivo), method of combination analysis (determination of 
the fractional inhibitory concentration (FIC), time-kill assay, among others), and the 
PMID and URL of the publication. 
Besides producing a high-quality reconstruction of known AMP interactions, this 
manual curation provided a “gold standard” for text mining. Notably, authors were 
able to identify the main elements of information to be collected as well as challenges 
in the interpretation of texts. The outputs of two public text mining tools were then 
evaluated – Chilibot [8] and PubTator [9].  
3 Results and Discussion 
3.1 AMP Literature Curation 
From a total of 203 papers resulting from our PubMed search, 132 papers were manu-
ally curated. Some papers were excluded (37 %) on the basis of their relevance to the 
topic. Notably, these papers do not mention AMPs, P. aeruginosa as target and/or 
cover for antitumor and food preservation areas. Review works were also excluded 
(9.1 %), since most would represent repeated data from the other curated papers 
whilst they do not provide necessary details on the experiments. Then, some interest-
ing evidences arose from the analysis of the information retrieved from the literature 
(Table 1).  
Regarding the mode of bacterial growth, 91 % of the studies focused on the use of 
combinations on planktonic cells, and, surprisingly, only 3 % of the studies covered 
the biofilm mode of growth. Biofilms are recognized as one of the main causes of 
several infections in humans [10], being highly related to nosocomial and chronic 
infections, and more resistant to treatment [2]. As such, more studies should be devot-
ed to AMP combinations towards biofilm treatment. 
Most of the combinations (80 %) involved one AMP combined with another com-
pound, mainly traditional antibiotics. This is linked to the rational that AMPs can 
enhance the activity of antibiotics, which act upon intracellular targets, by disrupting 
the cell membrane and facilitating the access within the cell. In terms of the bacterial 
strains most used, these studies focused on the reference strain P. aeruginosa ATCC 
27853, P. aeruginosa PAO1, and clinical isolates. Finally, the determination of the 
fractional inhibitory concentration (FIC) and the time-kill assays stand out as the most 
common methods for synergy assessment, which is in concordance with recent re-
views of the field [1]. 
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Table 1. Statistics on the manual curation process. Legend: * - not in the network; ** - info 
retrieved from abstract; could be on the network. 
No. of papers (%) No. of combinations (%) 
Total curated 132 (100) - 
Off topic* 49 (37) - 
Reviews* 12 (9.1) - 
Manuscript not available/different language** 
 
16 (12) 
 
- 
 
Total in the network 56 (100) 193 (100) 
Mode of growth 
Biofilm 2 (3.6) 3 (1.6) 
Planktonic 51 (91) 187 (97) 
In vivo 7 (13) 8 (4.1) 
Unknown 2 (3.6) 3 (1.6) 
Combination with 
AMPs 18 (32) 39 (20) 
Antibiotics and others 48 (86) 154 (80) 
 
Regarding the text mining approaches, the success of the tools tested in automatically 
curate AMP knowledge was poor. Chilibot limits the search to a maximum of 50 terms 
at a time. So, it is not possible to execute a systematic screening of interactions among 
all known AMPs (using AMP database records as input, for example). In turn, PubTator 
does not recognize most AMPs as chemical entities. Moreover, authors became aware 
that full-text curation should be a requirement for this line of reconstruction. Most ab-
stracts do not cover all combinations tested, focusing only on the best outcomes, and a 
great part do not give information about strains and methodology. 
3.2 Network Topology 
The constructed network (Figure 1) is represented as a non-oriented graph, containing 
121 nodes, representing AMPs and other antimicrobial compounds, and 193 edges, 
each correspondent to a combination. The network is non-homogeneous, with an inte-
rior containing highly connected drugs and an exterior comprised of some drugs with 
low interactions. Each node is linked to an average of 3 nodes, which means that each 
AMP was combined with an average of 3 antimicrobials.  
The network is dominated by a small number of highly connected nodes. The col-
ors on the nodes on Figure 1 correspond to their degree of connectivity, i.e. the num-
ber of nodes to which they are directly connected, ranging from the highly connected 
nodes (red) to nodes with only one connection (green). The most highly connected 
node (degree = 49), hence the most used compound in studies concerning AMP com-
binations, is colistin. Colistin (polymyxin E) is an AMP currently used as a last re-
source treatment for P. aeruginosa infections in the respiratory tract of cystic fibrosis 
patients, as well as other MDR Gram negative bacterial infections [11]. The use of 
colistin combined with other antimicrobial could lower its dosage and, thus, the asso-
ciated toxicity. Colistin is followed in connectivity by polymyxin B (degree = 19), 
which belongs to the same family of AMPs, which indicates a preference for 
polymyxins in combination studies towards P. aeruginosa. 
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